Highest-materiality recent filing
KALA BIO launches AI infrastructure platform; licenses Researgency from Younet AI
Exclusive worldwide license to Researgency platform for biotech field; initial 12-month term with renewal options.
KALA BIO CEO & CFO David Lazar resigns; director Avi Minkowitz appointed same day
David Lazar resigned as CEO and CFO effective Feb 2, 2026, remains on board.
KALA BIO sells $4.2M Series AAA Preferred, board control shifts to AK Holdings
Company issued 2.1M shares of Series AAA Preferred at $2/sh, raising $4.2M; each share convertible into 420 common shares (882M total potential shares).
KALA BIO receives Nasdaq bid price deficiency notice; 180-day compliance period until July 20, 2026
Letter dated Jan 20, 2026; closing bid price below $1.00 for 30 consecutive business days (Dec 3, 2025–Jan 16, 2026).
KALA BIO enters $15M at-market offering agreement with H.C. Wainwright
Aggregate market value of shares eligible for sale under ATM prospectus supplement currently $15,000,000.
KALA BIO settles $10.6M Oxford debt for $2M; issues 4.6M shares to settle claims
Paid $2M to Oxford Finance, settling ~$10.6M debt obligations in full; debt overhang removed.
Kala Bio pays $2M to settle $10.6M Oxford debt; loan obligations fully satisfied
Paid Oxford Finance $2 million on Dec 26, 2025 under prior Settlement Agreement.
KALA Bio dismisses Deloitte, appoints HTL as auditor; 6 directors offer conditional resignations
Audit committee approved HTL International as independent auditor for FY 2025, replacing Deloitte & Touche.
KALA BIO CEO Lazar sells Series AAA preferred rights; consultant hired for strategic alternatives
Annual meeting set for Jan 30, 2026; stockholder proposals and director nominations due Dec 27, 2025.
KALA BIO raises $10M in registered direct offering of common stock and pre-funded warrants
Sold 900K shares and pre-funded warrants for 9.1M shares at $1.00 per share (warrants at $0.9999).
KALA BIO enters $6M private placement, resolves Oxford default, appoints David Lazar as CEO
First closing raised $1.8M from 900k Series AA preferred shares at $2/share; second closing up to $4.2M subject to stockholder approval.
KALA BIO receives Nasdaq deficiency notice for MVLS below $35M; 180 days to comply
Nasdaq notified KALA BIO on Nov 10, 2025 that MVLS was below $35M for 30 consecutive business days, violating Listing Rule 5550(b)(2).
KALA Bio enters $375k convertible loan; Oxford pauses foreclosure, company faces cash crunch
Convertible loan of up to $375k from individual investor; first $187.5k due Nov 10, remainder by Nov 12, 2025.
KALA BIO faces asset foreclosure by Oxford; CEO terminated, all staff reduced, expects delisting
Oxford Finance forecloses on all assets, swept substantially all cash; still owed ~$9.6M.
KALA halts pipeline, cuts 51% of staff, grants retention bonuses to top executives
Ceased development of KPI-012 and stem cell platform; workforce reduced by ~19 employees (~51%).
KALA BIO receives default notice from Oxford; $29.1M debt accelerated
Oxford Finance declared event of default under Loan Agreement citing Material Adverse Change.
KALA BIO Phase 2b trial fails; KPI-012 development halted; workforce cut 51%
CHASE Phase 2b trial of KPI-012 for PCED did not meet primary endpoint of complete healing at Week 8; secondary endpoints also failed.
KALA BIO appoints Todd Bazemore as permanent CEO; board election, updated compensation
Todd Bazemore appointed CEO effective Aug 29, 2025, replacing his interim CEO role; also elected Class II director.
KALA BIO completes enrollment in Phase 2b trial of KPI-012 for PCED; topline data expected Q3 2025
CHASE trial randomized 79 patients across 37 sites in US and Latin America.
KALA BIO Q1 net loss $8.9M; cash $42.2M; KPI-012 Phase 2b topline data due Q3 2025
Cash and cash equivalents of $42.2M as of March 31, 2025, expected to fund operations into Q1 2026.
KALA BIO posts Q4 net loss of $8.2M; Phase 2b topline data delayed to 3Q25
Randomized 87 patients in Phase 2b CHASE trial for KPI-012; extending enrollment due to 13 unverified patients; topline data now expected in 3Q25.
Kala Bio CEO Mark Iwicki resigns; Todd Bazemore named interim CEO
Mark Iwicki resigned as CEO effective Feb 11, 2025; remains Chair of Board.
KALA BIO raises $10.75M in private placement; cash runway into Q1 2026
Gross proceeds of $10.75M from 1,340,603 common shares at $6.44 and 3,286 Series I preferred shares at $644.
KALA BIO reports Q2 net loss of $9.6M, cash $54.2M; Phase 2b data due Q1 2025
Net loss of $9.6M ($3.16 per share) for Q2 2024 vs. $10.4M ($4.36 per share) a year ago.
KALA BIO raises $12.5M in private placement; extends cash runway into Q4 2025
Gross proceeds of ~$12.5M from sale of 1,197,314 common shares at $5.85 and 9,393 Series H preferred shares at $585.00.
KALA BIO Q1 net loss $11.8M; Phase 2b CHASE trial enrolling, topline data by year-end 2024
Phase 2b CHASE trial of KPI-012 for PCED enrolling; topline data expected by year-end 2024.
KALA BIO reports FY23 net loss $42.2M; Phase 2b PCED trial data expected YE 2024
Q4 2023 net loss $8.6M ($3.18/sh) vs $12.8M ($7.97/sh) in Q4 2022.
Kala Bio targeting CHASE Phase 2b data for KPI-012 (PCED) by end of 2024
Topline safety and efficacy data from CHASE Phase 2b trial expected by year-end 2024.
KALA BIO Q3 2023 net loss $8.7M; CHASE Phase 2b enrollment ongoing, topline data 2H 2024
Net loss $8.7M ($3.41 per share) vs net income $29.1M in Q3 2022 due to prior year gain on sale of commercial business.
KALA BIO Q2 net loss $10.4M; cash $59.2M; CHASE trial topline data expected Q2 2024
Net loss of $10.4M ($4.36/share) vs $28.1M ($18.92/share) in Q2 2022; operating loss $9.6M.
Kala Pharma Q1 net loss $14.5M; KPI-012 CHASE Phase 2b enrolling with topline data Q1 2024
Q1 2023 net loss $14.5M ($6.99/share) vs $32.9M ($22.18/share) in Q1 2022; no product revenue post-Alcon sale.
Kala subsidiary awarded $15M CIRM grant for KPI-012 PCED Phase 2b trial
CIRM awarded Combangio a $15M grant to support KPI-012 for persistent corneal epithelial defect.
Kala Pharma reports positive safety data in CHASE Phase 2b trial of KPI-012; second cohort initiated
Both patients in open-label first cohort (high dose 3 U/mL QID) completed at least 1 week with no safety issues.
Kala enrolls first patient in PCED trial, closes $31M private placement
Enrolled first patient in CHASE Phase 2b trial of KPI-012 for persistent corneal epithelial defect; top-line data targeted for Q1 2024.
Kala Pharma enters $40M ATM equity facility with Jefferies, prepays $10M Oxford loan
New Open Market Sale Agreement with Jefferies for up to $40M in common stock at market prices; Jefferies gets up to 3% commission.
On February 11, 2025, Mark Iwicki notified KALA BIO, Inc. (the “Company”) of his decision to resign as the Chief Executive Officer of the Company, effective immediately.
On February 11, 2025, the Board appointed Todd Bazemore as the interim Chief Executive Officer and principal executive officer of the Company, effective immediately.
On September 23, 2024, Mark S. Blumenkranz, M.D. notified KALA BIO, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company, effective immediately.
On October 31,, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of Kala Pharmaceuticals, Inc. (the “Company”), the Board of Directors of the Company (the “Board”) appointed Marjan Farid, M.D. as a member of the Board, effective immediately.
Mark Iwicki will continue to lead the Company as its Chief Executive Officer and as Chairman of the Board of Directors but will no longer serve as President of the Company.
On December 16, 2021, the Board of Directors of Kala Pharmaceuticals, Inc. (the “Company”) appointed Todd Bazemore, the Company’s Chief Operating Officer, to serve as the Company’s President and Chief Operating Officer, effective immediately.
Upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”), the Board appointed Mark Blumenkranz as a member of the Board, effective upon the Closing of the Acquisition
On October 14, 2021, Rajeev Shah notified Kala Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors of the Company (the “Board”), which resignation was effective on October 15, 2021.
On October 15, 2021, upon the recommendation of the Nominating and Corporate Governance Committee, the Board appointed C. Daniel Myers as a member of the Board, effective immediately, to fill the vacancy created by the resignation of Mr. Shah.
Max materiality 1.00 · Median 0.60 · Most common event other_material